JP7584405B2 - 改変されたサイトメガロウイルスタンパク質及び安定化された複合体 - Google Patents

改変されたサイトメガロウイルスタンパク質及び安定化された複合体 Download PDF

Info

Publication number
JP7584405B2
JP7584405B2 JP2021521000A JP2021521000A JP7584405B2 JP 7584405 B2 JP7584405 B2 JP 7584405B2 JP 2021521000 A JP2021521000 A JP 2021521000A JP 2021521000 A JP2021521000 A JP 2021521000A JP 7584405 B2 JP7584405 B2 JP 7584405B2
Authority
JP
Japan
Prior art keywords
seq
fragment
amino acid
hcmv
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505094A5 (https=
JP2022505094A (ja
Inventor
マリト，エンリコ
ジェームス ボトムリー，マシュー
カーフィ，アンドレア
チャンドラモウリ，スマナ
ルイスィ，ケイト
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2022505094A publication Critical patent/JP2022505094A/ja
Publication of JP2022505094A5 publication Critical patent/JP2022505094A5/ja
Application granted granted Critical
Publication of JP7584405B2 publication Critical patent/JP7584405B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021521000A 2018-10-17 2019-10-15 改変されたサイトメガロウイルスタンパク質及び安定化された複合体 Active JP7584405B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746804P 2018-10-17 2018-10-17
US62/746,804 2018-10-17
PCT/IB2019/058777 WO2020079586A1 (en) 2018-10-17 2019-10-15 Modified cytomegalovirus proteins and stabilized complexes

Publications (3)

Publication Number Publication Date
JP2022505094A JP2022505094A (ja) 2022-01-14
JP2022505094A5 JP2022505094A5 (https=) 2022-10-31
JP7584405B2 true JP7584405B2 (ja) 2024-11-15

Family

ID=68296588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521000A Active JP7584405B2 (ja) 2018-10-17 2019-10-15 改変されたサイトメガロウイルスタンパク質及び安定化された複合体

Country Status (8)

Country Link
US (2) US11932669B2 (https=)
EP (1) EP3866845A1 (https=)
JP (1) JP7584405B2 (https=)
CN (1) CN113271968B (https=)
BR (1) BR112021006812A2 (https=)
CA (1) CA3116175A1 (https=)
MX (1) MX2021004273A (https=)
WO (1) WO2020079586A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
EP4526327A1 (en) * 2022-05-20 2025-03-26 GlaxoSmithKline Biologicals S.A. Modified varicella zoster virus glycoprotein e proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509013A (ja) 1999-06-25 2003-03-11 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド 安定化されたウィルスエンベロープタンパク質とその使用
WO2015181142A1 (en) 2014-05-27 2015-12-03 Glaxosmithkline Biologicals S.A. Cytomegalovirus complexes and uses thereof
WO2018182983A1 (en) 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388186A1 (en) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company External regulation of gene expression
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
EP2320945A4 (en) 2008-07-30 2013-02-27 Emergent Biosolutions Inc STABLE MILZBRANDIMPFSTOFFFORMULIERUNGEN
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CA2885145A1 (en) 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
MX2016014660A (es) 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509013A (ja) 1999-06-25 2003-03-11 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド 安定化されたウィルスエンベロープタンパク質とその使用
WO2015181142A1 (en) 2014-05-27 2015-12-03 Glaxosmithkline Biologicals S.A. Cytomegalovirus complexes and uses thereof
WO2018182983A1 (en) 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same

Also Published As

Publication number Publication date
CN113271968A (zh) 2021-08-17
US20210277067A1 (en) 2021-09-09
US12384819B2 (en) 2025-08-12
US20240383949A1 (en) 2024-11-21
JP2022505094A (ja) 2022-01-14
US11932669B2 (en) 2024-03-19
CN113271968B (zh) 2024-06-14
EP3866845A1 (en) 2021-08-25
MX2021004273A (es) 2021-12-10
WO2020079586A1 (en) 2020-04-23
WO2020079586A9 (en) 2021-05-06
BR112021006812A2 (pt) 2021-07-20
CA3116175A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US12384819B2 (en) Modified cytomegalovirus proteins and stabilized complexes
US20250009874A1 (en) Modified cytomegalovirus proteins and stabilized complexes
KR102236497B1 (ko) 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
JP7770382B2 (ja) ヒトサイトメガロウイルスｇｂポリペプチド
SG11202110646PA (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
US20140348865A1 (en) Immunogens based on an hiv-1 v1v2 site-of-vulnerability
US20240189416A1 (en) Stabilized coronavirus spike protein fusion proteins
CN118580323B (zh) Rsv融合前f蛋白的突变体及其制备和应用
CA3117390A1 (en) Recombinant gp120 protein with v1-loop deletion
HK40024599A (en) Modified cytomegalovirus proteins and stabilized complexes
WO2016141201A2 (en) Rational vaccine design for hepatitis c virus
HK40112146A (zh) Rsv融合前f蛋白的突变体及其制备和应用
HK40112146B (zh) Rsv融合前f蛋白的突变体及其制备和应用
EP4046653A1 (en) Immunogenic polypeptides and uses thereof
CA3012267C (en) Truncated glycoprotein g of herpes simplex virus 2
HK40111374A (zh) Rsv pre-f突变体及其生产方法和用途
HK40111374B (zh) Rsv pre-f突变体及其生产方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241105

R150 Certificate of patent or registration of utility model

Ref document number: 7584405

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150